| A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects S Talukdar, Y Zhou, D Li, M Rossulek, J Dong, V Somayaji, Y Weng, ... Cell metabolism 23 (3), 427-440, 2016 | 479 | 2016 |
| Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and … J Gu, Y Weng, QY Zhang, H Cui, M Behr, L Wu, W Yang, L Zhang, X Ding Journal of Biological Chemistry 278 (28), 25895-25901, 2003 | 246 | 2003 |
| Chemical modification study of antisense gapmers R Stanton, S Sciabola, C Salatto, Y Weng, D Moshinsky, J Little, E Walters, ... Nucleic acid therapeutics 22 (5), 344-359, 2012 | 157 | 2012 |
| Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese … AM Kim, VR Somayaji, JQ Dong, TP Rolph, Y Weng, JR Chabot, ... Diabetes, Obesity and Metabolism 19 (12), 1762-1772, 2017 | 138 | 2017 |
| Expression of cytochrome p450 and other biotransformation genes in fetal and adult human nasal mucosa X Zhang, QY Zhang, D Liu, T Su, Y Weng, G Ling, Y Chen, J Gu, ... Drug Metabolism and Disposition 33 (10), 1423-1428, 2005 | 105 | 2005 |
| Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice Y Weng, C Fang, RJ Turesky, M Behr, LS Kaminsky, X Ding Cancer Research 67 (16), 7825-7832, 2007 | 101 | 2007 |
| Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450 L Wu, J Gu, H Cui, QY Zhang, M Behr, C Fang, Y Weng, K Kluetzman, ... Journal of Pharmacology and Experimental Therapeutics 312 (1), 35-43, 2005 | 82 | 2005 |
| Hepatic gene expression changes in mouse models with liver-specific deletion or global suppression of the NADPH-cytochrome P450 reductase gene: mechanistic implications for the … Y Weng, CC DiRusso, AA Reilly, PN Black, X Ding Journal of Biological Chemistry 280 (36), 31686-31698, 2005 | 80 | 2005 |
| Conditional knockout of the mouse NADPH‐cytochrome p450 reductase gene L Wu, J Gu, Y Weng, K Kluetzman, P Swiatek, M Behr, QY Zhang, X Zhuo, ... Genesis 36 (4), 177-181, 2003 | 76 | 2003 |
| Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin … Y Weng, JR Chabot, B Bernardo, Q Yan, Y Zhu, MB Brenner, C Vage, ... PloS one 10 (3), e0119104, 2015 | 69 | 2015 |
| Establishing transcriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes JE Moscovitz, AS Kalgutkar, K Nulick, N Johnson, Z Lin, TC Goosen, ... Journal of Pharmacology and Experimental Therapeutics 365 (2), 262-271, 2018 | 52 | 2018 |
| Discovery of PF-06835919: a potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose K Futatsugi, AC Smith, M Tu, B Raymer, K Ahn, SB Coffey, MS Dowling, ... Journal of Medicinal Chemistry 63 (22), 13546-13560, 2020 | 49 | 2020 |
| Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction JA Gutierrez, W Liu, S Perez, G Xing, G Sonnenberg, K Kou, M Blatnik, ... Molecular Metabolism 48, 101196, 2021 | 48 | 2021 |
| Discovery of fragment-derived small molecules for in vivo inhibition of ketohexokinase (KHK) K Huard, K Ahn, P Amor, DA Beebe, KA Borzilleri, BA Chrunyk, SB Coffey, ... Journal of medicinal chemistry 60 (18), 7835-7849, 2017 | 41 | 2017 |
| Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model Y Wei, H Wu, L Li, Z Liu, X Zhou, QY Zhang, Y Weng, J D'Agostino, G Ling, ... Drug Metabolism and Disposition 40 (6), 1144-1150, 2012 | 38 | 2012 |
| Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD H Neubert, S Fountain, L King, T Clark, Y Weng, DM O’Hara, W Li, ... Bioanalysis 4 (21), 2589-2604, 2012 | 34 | 2012 |
| Analysis of testosterone and dihydrotestosterone in mouse tissues by liquid chromatography–electrospray ionization–tandem mass spectrometry Y Weng, F Xie, L Xu, D Zagorevski, DC Spink, X Ding Analytical biochemistry 402 (2), 121-128, 2010 | 32 | 2010 |
| Discovery of orally bioavailable selective inhibitors of the sodium-phosphate cotransporter NaPi2a (SLC34A1) KJ Filipski, MF Sammons, SK Bhattacharya, J Panteleev, JA Brown, ... ACS Medicinal Chemistry Letters 9 (5), 440-445, 2018 | 30 | 2018 |
| Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21–antibody Protein conjugate C Giragossian, C Vage, J Li, K Pelletier, N Piché-Nicholas, ... Drug Metabolism and Disposition 43 (6), 803-811, 2015 | 25 | 2015 |
| Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics SC Humphreys, JA Davis, S Iqbal, A Kamel, K Kulmatycki, Y Lao, X Liu, ... Nucleic acids research 50 (11), 6020-6037, 2022 | 24 | 2022 |
Jeff ChabotPfizer, Inc.Dirección de correo verificada de pfizer.com
